Rationale, design, and progress of the ENHanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment


Correspondence: Vijay K. Sharma*, Division of Neurology, Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074. E-mail: drvijay@singnet.com.sg

1Department of Neurology, Peking University First Hospital, Beijing, China
2Division of Neurology, Department of Medicine, National University Hospital and YLL School of Medicine, National University of Singapore, Singapore
3Department of Cardiovascular Sciences and NIHR Biomedical Research Unit, University of Leicester University, Leicester, UK
4The George Institute for Global Health, Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia
5Asan Medical Center, University of Ulsan, Seoul, South Korea
6Clinica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile
7Universidad de Chile, Santiago, Chile
8Stroke Unit, Ho Chi Minh City, Vietnam
9Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan
10John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, Newcastle, Australia
11Calgary Stroke Program, Department of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada
12Stroke trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK
13Departments of Neurology and Rehabilitation Medicine and Radiology, University of Cincinnati Neuroscience Institute, University of Cincinnati Academic Health Center, Cincinnati, OH, USA
14The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
15Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio grande do Sul, Rio Grande do Sul, Brazil
16Stroke Service – Neurology Division, Department of Neuroscience and Behavior, Ribeirão Preto School of Medicine, University of Sao Paulo, Ribeirão Preto, SP, Brazil
17Fundación Cardiovascular, Bucaramanga, Colombia
18Department of Neurology, Christian Medical College, Ludhiana, India
19Direttore, UO Neurologia, USL Umbria 1, Sedi di Città di Castello e Branca, Italy
20Department of Neurology, APHP – Hôpital Lariboisière and DHU NeuroVasc Paris – Sorbonne, Univ Paris Diderot – Sorbonne Paris Cité, Paris, France
21The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Received: 3 December 2014; Accepted: 8 March 2015; Online publication:

Conflict of interest: C Anderson reports receiving fees for Advisory Panels of The Medicines Company and Pfizer, and speaking at seminars for Takeda China, Coviden and Bayer. J Broderick has received research monies to Department of Neurology from Genentech for PRISMS Trial; travel to Australian Stroke Unit Heads conference in 2013 paid for by Boehringer Ingelheim; study medication from Genentech and study catheters supplied during Protocol Versions 1–3 by Concentric Inc, EKOS Corp, and Cordis Neurovascular for the third Interventional Management of Stroke (IMS III) trial.

Trial Registration: The study is registered at ClinicalTrials.gov (NCT01422616), ISRCTN Register (ISRCTN82387104) and Australian New Zealand Clinical Trial Registry (ACTRN12611000236998).

Funding: The study is funded by the National Health and Medical Research Council (NHMRC) of Australia (Project Grant 1020462), the Stroke Association of United Kingdom (Reference TSA 2012/01), and the National Council for Scientific and Technological Development of Brazil (CNPq grant number 467322/2014-7).

DOI: 10.1111/jis.12486
Protocol

Y. Huang et al.

2 × 2 quasi-factorial, active-comparison, prospective, random-
ized, open blinded endpoint (PROBE), clinical trial that is evalu-
ating Arm [A] ‘rt-PA dose’ and/or Arm [B] ‘BP control’, using
central Internet randomization and data collection in patients
fulfilling local criteria for thrombolysis and clinician uncer-
tainty over the study treatments. The treatment arms will be
analyzed separately.

Study outcomes The primary study outcome in both trial Arms
is death or disability according to the modified Rankin scale
(mRS, scores 2–6) assessed at 90 days. Secondary outcomes
include sICH, any ICH, a shift (‘improvement’) in function
across mRS scores, separately on death and disability, early
neurological deterioration, recurrent major vascular events,
health-related quality of life, length of hospital stay, need for
permanent residential care, and health care costs.

Results Following launch of the trial in February 2012, the
study has recruited more than 2500 patients across a global
network of approximately 100 sites in 15 countries. The
required sample sizes are 3300 for Arm [A] and 2300 for Arm
[B], which will provide >90% power to detect non-inferiority
of low-dose iv rt-PA and superiority of intensive BP lowering
on the primary clinical outcome, respectively.

Conclusions Low-dose iv rt-PA and early intensive BP lowering
could provide more affordable and safer use of thrombolytic
treatment for patients with AIS worldwide.

Key words: acute ischaemic stroke, Alteplase, dose, hypertension, rt-PA,
thrombolysis

Introduction and rationale

Intravenous (iv) recombinant tissue plasminogen activator (rt-
PA) (or Alteplase) remains the only approved drug for achieving
early recanalization of an occluded intracranial artery in the
setting of acute ischaemic stroke (AIS), and the earlier the treat-
ment is given the bigger the proportional benefit (1,2). Use of iv
rt-PA in AIS was licensed on the basis of the pivotal National
Institute of Neurological Disorders and Stroke (NINDS) trial (3),
where an iv dose of 0·9 mg/kg body weight (10% as bolus, 90% as
a one-hour infusion; maximum dose 90 mg), chosen on the basis
of small dose-escalation studies (4–6), was shown to improve
outcomes when given to carefully selected patients within three-
hours of symptom onset. On the basis of a meta-analysis of the
initial clinical trials of iv rt-PA (7) and the later positive third
European Cooperative Acute Stroke Study (ECASS III) (8), most
guidelines now recommend an extension of the time criteria to
4·5 h in those AIS patients without severe neurological deficit or
clear major risks (9). The totality of the current evidence among
nearly 7,000 patients randomized trials of thrombolyis is now
strong for iv rt-PA providing an overall net benefit despite a 2–7%
risk of major symptomatic intracerebral haemorrhage (sICH)
(1,2). Despite the early risk of fatal ICH (2–3%), patients who
receive iv rt-PA within a few hours after the onset of AIS have an
overall ≥ 30% relative increased chance of having little or no
residual disability (1,2). A consideration of the entire spectrum of
clinically important outcomes relevant to the use of rt-PA within
three-hours of onset of AIS indicates a number needed to benefit
of 3 compared to a number need to harm of 30 (10).

Low-dose (0·6 mg/kg body weight; maximum 60 mg) of iv
rt-PA was first evaluated in 3 small double-blind randomized
controlled trials of duteplase (which is similar to rt-PA) in
patients within six-hours of onset of AIS in Japan over 20 years
ago (11,12). The results showed that 20 mega-international units
(MIU) of duteplase (equal to 0·33 MIU/kg or 0·6 mg/kg of rt-PA)
was superior to placebo and comparable to 30 MIU on both
angiographic recanalization and clinical improvement. Impor-
tantly, massive ICH was more frequent in patients who received
30 MIU of duteplase. Low-dose rt-PA was subsequently approved
for use in Japan because of concerns of higher risk of ICH in this
population due to potential racial differences in coagulation-
ﬁbrinolysis factors (13), plasma concentrations of fibrinogen and
plasminogen activator inhibitor (14), and genetic polymorphisms
of coagulation factors (15). Interestingly, careful in-vitro studies
indicate no further increase in the degree of clot lysis with rt-PA
doses greater than 0·6 mg/kg (16). Moreover, use of a lower dose
of rt-PA (0·5–0·75 mg/kg) for patients with acute myocardial
infarction in Japan has resulted in rates of coronary artery patency
comparable with the standard dose (1–1·25 mg/kg) used in other
countries (13). The Japan Alteplase Clinical Trial (J-ACT) (17),
undertaken with 0·6 mg/kg rt-PA in an open non-randomized
evaluation of patients within three-hours of AIS, showed equiva-

cent clinical outcomes but a reduced risk of sICH compared to
the standard 0·9 mg/kg dose. J-ACT and comparable data from sub-
sequent registries (18,19) led to regulatory approval of the
0·6 mg/kg dose as the standard treatment for AIS patients in
Japan. However, this policy has led to confusion among clinicians
in other parts of Asia as to the balance of benefits and risks of low-
vs. standard-dose rt-PA. Thus, 0·6 mg/kg dose of rt-PA (which
often requires use of only a single 50 mg vial of Actylise® Boeh-
ringer Ingelheim or Ateplase® Genentech) has become an attrac-
tive ‘low-cost’ and possibly ‘safer’ option for elderly patients and
for those who cannot afford the full dose. The high cost of rt-PA
(∼US$2,000 per 2 × 50 mg vials for 0·9 mg/kg dose) is a major
out-of-pocket expense for many people in fee-for-service health
care systems of low-middle income countries (20). A recent sys-
temic review of the published studies demonstrates wide vari-
ations in iv rt-PA dose regimes, therapeutic response, and risk of
sICH across Asian patients (21). However, this study did not
derive any conclusive differences in the therapeutic response or
risk of sICH related to either rt-PA dose regimes in Asians, and
acknowledged a lack of randomized evidence to support a wide-
spread policy for low-dose iv rt-PA in patients with AIS. Addi-
tionally, the racial differences in coagulation factors and
differential effects of low-dose rt-PA in some Asian studies could
simply be due to the lower total dose given for a smaller body
weight or a lower ‘clot volume’ due to the greater proportion of
small vessel occlusive or ‘lacunar’ forms of AIS as compared to
more large vessel and cardio-embolic strokes (high clot volume)
in non-Asians. Accordingly, a Cochrane review emphasized no
clear differences in indirect comparisons of different dosages of
thrombolytic agents, which in the absence of head-to-head direct
comparative studies, means there is uncertainty over the relative
benefits and risks of low- vs. standard-dose rt-PA (22).

Another controversial issue in patients with AIS is the optimal
management of co-occurring hypertension. Elevated systolic BP
(>140 mmHg) is very common (>60%) early after the onset of
AIS (23,24), with greater increases in BP evident in those patients

© 2015 World Stroke Organization
with pre-existing hypertension and larger strokes (25,26). While positive associations between increased systolic BP and poor outcome are generally documented, very low (<130 mmHg) systolic BP and large reductions in systolic BP are also associated with poor outcomes in AIS (24). Various explanations for elevated systolic BP in acute stroke include acute physiological stress, pain, unstable pre-existing hypertension or increased intracranial pressure. However, the observed U- or J-shaped relationship of BP and outcome (25,26) in patients with AIS may not be causally related. Patients with more severe strokes may have a more prominent autonomic response, and they may also develop lower BP levels as their condition worsens. Experimental models of focal cerebral ischaemia and reperfusion indicate that BP reduction reduces the size of cerebral ischaemia and improves reperfusion (27). Even so, any potential benefits of rapid lowering of BP in AIS must be balanced the risks of worsening ischaemia from potential hypoperfusion where autoregulation is failing within the ischaemic penumbra.

Although guidelines for BP control in AIS are consistent in contraindicating use of rt-PA in patients with uncontrolled BP (systolic > 185 and diastolic > 110 mmHg) (9), recent data suggest that lower BP levels are associated with better outcomes, particularly in those patients treated with iv rt-PA. In the original NINDS study (3), use of antihypertensive therapy was common in placebo as well as the active groups. Although BP treatment did not appear to influence outcomes, the small sample size (n = 624) and lack of randomized variation precluded firm conclusions to be drawn (28). Subsequent non-randomized studies indicate that ‘inadequate control’ of BP prior to, and after the use of rt-PA, is associated with a higher likelihood of sICH (29). The most compelling data are from the large Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) registry (30) of 6483 patients and the Safe Implementation of Thrombolysis in Stroke–International Stroke Thrombolysis Register (SITS-ISTR) (31) of 11,080 patients with expanded measures including serial BP (baseline, 2 and 24 h), treatment and outcome data. In SITS-MOST, sICH occurred in 8-5% (95% confidence intervals [CI] 8-9%) patients and was associated with elevated baseline systolic BP (odds ratio [OR] 1-3, 95% CI 1-1-1-7 per 20 mmHg standard deviation) (30). Similarly, in SITS-ISTR, multivariable analyses showed that elevated systolic BP as a continuous variable was associated with a worse outcome (P < 0.001) and as a categorical variable had a linear association with sICH (31). A U-shaped association for death and dependency was evident, with best outcome in the nadir systolic BP 141–150 mmHg, with sICH being four times higher in patients with a systolic BP > 170 mmHg as compared to those with levels of 141–150 mmHg (31). All these data indicate that a ≥215 mmHg difference in systolic BP levels equates to ≥215% reduction in a poor outcome after rt-PA. Thus, guidelines for the management of BP in AIS highlight the need for a definitive study, since their expert-derived recommendations (<185 mmHg systolic BP before rt-PA and <180 mmHg after rt-PA) provide only an indication of perceived harm from high BP (9). Neither the Scandinavian Candesartan Acute Stroke Trial (SCAST) (32) nor the recently completed Efficacy of Nitric Oxide in Stroke (ENOS) (33) trial were specifically designed to address the role of very early (within a few hours), rapid and intensive BP lowering, in patients AIS who receive rt-PA. Importantly, the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT-2), which showed that rapid BP lowering (systolic target < 140 mmHg) is feasible, safe and improves functional outcome possibly by attenuating ICH expansion from reduced cerebral perfusion pressure, provides further rationale to test the efficacy of such a protocol in AIS patients treated with rt-PA (34).

Based on this background, we initiated the ENCHANTED trial to determine the impact of low-dose rt-PA and intensive BP lowering on death and disability defined by the modified Rankin scale (mRS) (35) at 90 days in AIS patients who are eligible to receive thrombolysis treatment. Herein, we outline the study protocol with several modifications, and progress to date.

### Objectives

The ENCHANTED trial includes two parallel interventional Arms, the primary aims of which are to evaluate whether:

1. Compared with standard-dose, low-dose iv rt-PA is non-inferior for the clinical outcome of death or disability at 90 days (the corresponding null hypothesis is that low-dose is inferior to standard-dose rt-PA), and
2. Compared with standard guideline-recommended BP management, early intensive BP lowering is superior for the clinical outcome of death or disability at 90 days (the corresponding null hypothesis is that there is no difference in frequency of this outcome between randomized groups).

The secondary objectives are to determine whether:

1. Compared to standard-dose, low-dose iv rt-PA reduces the risk of sICH (the corresponding null hypothesis is that there is no difference in the frequency of sICH between groups of differing doses of iv rt-PA), and
2. Compared to guideline-recommended BP management, early intensive BP lowering after iv rt-PA reduces the risk of any ICH (the corresponding null hypothesis is that there is no difference in the rate of any ICH between groups of differing intensities of BP lowering).

This outcome of any ICH was changed from sICH in the protocol in November 2013 in line with a reduction in sample size for Arm [B] ‘BP intensity’ from 3,300 to 2,300 patients. We undertook this change because recruitment into Arm [B] was slower than projected and it was not feasible for the study to achieve the original planned sample size to determine superiority of intensive BP lowering on the secondary ‘safety’ outcome of sICH. A lower sample size of 2300 was more realistic to determine safety for the alternative but still clinically relevant outcome of any ICH. The effects of early intensive BP lowering on sICH will be explored in analyses.

3. Other secondary outcomes are to define the effects on a shift (‘improvement’) in measures of disability according to full range of scores on the mRS (35); excellent and good functional outcomes; separately on death and disability; early neurological deterioration; recurrent acute myocardial infarction and AIS; health-related quality of life (HRQoL); length of hospital stay; need for permanent residential care; and health care costs.
Methods

Trial design
ENCHANTED is an independent, investigator-initiated and conducted, international, multicenter, 2 × 2 quasi-factorial, prospective, open-label, assessor-blinded end-point (PROBE), randomized controlled trial that involves a package of 2 linked comparative treatment Arms (‘rt-PA dose’ and ‘BP control’). The trial is being conducted in accordance with local and international regulatory and ethical requirements. All participating hospitals receive approval from required regulatory authorities, ethics committee (EC) or institutional review board (IRB), prior to initiation of the trial.

Trial population
Each hospital site is required to keep a log of all patients presenting with a diagnosis of AIS and who were considered for the study but subsequently excluded. The screening log records each patient’s initials and date of admission together with a brief description of the main reason as to why a patient was not randomized. The log is used by the research staff to monitor recruitment and identify specific barriers to randomization of eligible patients. It is also a requirement for reporting the results of clinical trials.

Study personnel consider all patients presenting with AIS for enrollment. Table 1 reports the ENCHANTED inclusion and exclusion criteria. To be eligible, patients must fulfill local criteria for use of iv rt-PA, and the attending clinician is required to sequentially consider their level of clinical uncertainty over the balance of potential benefits and risks pertaining to Arm [A] the appropriate dose of rt-PA and Arm [B] the level of BP control, in each particular patient. Patients will not be eligible if one or more of the following are noted: being unlikely to benefit from rt-PA (e.g. advanced dementia), deemed to have a very high likelihood of death within the next 24 h, or have another medical illness that is likely to interfere with either the outcome assessments or follow-up. Investigators are able to undertake all investigations according to their usual standard of care in their management of patients with AIS, including urgent referral for cerebral angiography for consideration of endovascular clot retrieval in selected sites. Thus, ENCHANTED is a pragmatic trial designed to evaluate the effectiveness of interventions in real-life routine best practice conditions.

Before participation, written consent is obtained from each participant or their approved surrogate for patients who are too unwell to comprehend the information. Study investigators may withdraw a patient from the trial at any time without prejudice and explanation. Alternatively, the study participants/legally acceptable representative can opt to withdraw at any stage, although efforts should still be undertaken to obtain outcome data at 90 days.

Baseline assessment before randomization
All patients receive the following assessments prior to randomization: clinical evaluation of stroke severity using the National Institutes of Health stroke scale (NIHSS) (36) and pre-ictus functional independence (mRS 0–2); non-contrast brain CT-scan (or MRI) with or without angiography (or perfusion) according to standard practice, to confirm the diagnosis of AIS and exclude ICH or a relevant structural abnormality; baseline characteristics (age, gender), risk factors (hypertension, diabetes mellitus, hyper-

Table 1 Inclusion/exclusion criteria for the ENCHANTED trial

<table>
<thead>
<tr>
<th>Patient specific inclusion criteria:</th>
<th>All patients are eligible if they fulfill general eligibility criteria for thrombolytic treatment with rt-PA as well as specific criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. are ≥ 18 years of age;</td>
<td>i. Specific criteria for Arm [A] of low-dose vs. standard-dose rt-PA</td>
</tr>
<tr>
<td>2. have a clinical diagnosis of acute ischaemic stroke confirmed by brain imaging;</td>
<td>a. Specific criteria for Arm [A] of low-dose vs. standard-dose rt-PA</td>
</tr>
<tr>
<td>3. are able to receive rt-PA treatment within 4·5 h of symptom onset;</td>
<td>i. No definite indication nor contraindication for either dose of rt-PA.</td>
</tr>
<tr>
<td>4. have a systolic blood pressure (BP) ≤ 185 mmHg (the guideline recommended level for use of rt-PA; patients with higher BP can still be included provided the BP is reduced to the entry level prior to commencement of rt-PA);</td>
<td>b. Specific criteria for Arm [B] of intensive vs. guideline recommended BP lowering</td>
</tr>
<tr>
<td>5. and fulfill other specific criteria for each arm</td>
<td>i. Patient will (or has) received i.v. rt-PA treatment, either a randomized dose within the trial or a physician decided dose as part of a standard care;</td>
</tr>
<tr>
<td></td>
<td>ii. Sustained elevated systolic BP level, defined as 2 readings ≥ 150 mmHg 2 minutes apart;</td>
</tr>
<tr>
<td></td>
<td>iii. Able to commence intensive BP lowering treatment within six-hours of stroke onset. This criteria was changed from 4·5 h of stroke onset in November 2013 to allow clinicians to fast-track use of rt-PA treatment in patients who were not participating in Arm [A] rt-PA dose, and allow a slightly longer time period in which to randomize patients into Arm [B] BP lowering, either intensive (target &lt; 140 mmHg systolic) or usual care.</td>
</tr>
<tr>
<td></td>
<td>iv. No definite indication or contraindication to immediate ‘intensive’ systolic BP lowering (to a target of 130–140 mmHg). The intensive BP lowering target was changed from 140–150 mmHg to 130–140 mmHg in the protocol in November 2013 to ensure that BP control is actually ‘intensive’ as compared to control group.</td>
</tr>
<tr>
<td>Patient specific exclusion criteria:</td>
<td>Patients will not be eligible if one or more of the following are noted:</td>
</tr>
<tr>
<td>1. unlikely to benefit from the therapy due to pre-existing disability (e.g. advanced dementia) or very high likelihood of death within 24 h;</td>
<td>1. unlikely to benefit from the therapy due to pre-existing disability (e.g. advanced dementia) or very high likelihood of death within 24 h;</td>
</tr>
<tr>
<td>2. has another medical illness that interferes with outcome assessments</td>
<td>2. has another medical illness that interferes with outcome assessments</td>
</tr>
<tr>
<td>3. is unlikely to adhere to follow-up procedures</td>
<td>3. is unlikely to adhere to follow-up procedures</td>
</tr>
<tr>
<td>4. not consenting to participate in ENCHANTED</td>
<td>4. not consenting to participate in ENCHANTED</td>
</tr>
<tr>
<td>5. previously enrolled in ENCHANTED</td>
<td>5. previously enrolled in ENCHANTED</td>
</tr>
</tbody>
</table>

© 2015 World Stroke Organization
choleraemia, coronary artery disease, atrial fibrillation) and prior use of antihypertensive medications; and a detailed clinical examination including vital signs (pulse, BP) and assessment of the neurological deficit (NIHSS).

Randomization

After confirmation of eligibility, patients are randomized via a central Internet-based system at The George Institute for Global Health in Sydney, Australia. This is done by connecting the study site to the server at the International Coordinating Centre (ICC) for registration and randomization of the patient. The randomization sequence uses a minimization algorithm to ensure balance in key prognostic factors, according to site of recruitment, time from the onset of symptoms (<3 vs. ≥3 h) and NIHSS score (<10 vs. ≥10 points). Once Arm A is completed, the randomization system will be programmed to allow randomization only of patients into Arm B.

The study was initially designed with a fixed time point for the randomization of patients into one or both Arms of the study. However, recruitment was slow for Arm [B] ‘BP control’ due to various factors including low frequency of ‘hypertensive patients’, investigator concerns that the extra time required to obtain consent was impacting on ‘door-to-needle’ (DTN) time quality performance, and requirement for greater monitoring of patients associated with administering more intensive BP lowering treatment. This led us to change the protocol in November 2013 by uncoupling the time of randomization for the Arms of the study. This allows investigators the option of randomizing patients into Arm [B] either (a) at the time of randomization into Arm [A], or (b) at a later time point within six-hours after the onset of AIS. This 6 hour time window from the onset of symptoms to the commencement of intensive BP lowering as an inclusion criterion for patients who have not been included in Arm [A] ‘rt-PA dose’, allows investigators to give rt-PA as part of usual care and then randomize patients into Arm [B] ‘BP control’. Given that most patients receive rt-PA at two- to three-hours after stroke onset, this change has meant that intensive BP lowering can commence within about three- to four-hours after administering the bolus dose of rt-PA.

Interventions

Site investigators have the choice of randomizing patients into one or both treatment Arms of the study: Arm [A] comprises standard-dose (0.9 mg/kg; 10% bolus and 90% infusion over 60 min; maximum 90 mg) or low-dose (0.6 mg/kg; 15% bolus and 85% infusion over 60 min; maximum 60 mg) iv rt-PA; and Arm [B] comprises intensive BP lowering (target systolic BP 130–140 mmHg within 60-minutes of randomization, and to maintain this level for at least 72 h, or hospital discharge [or death] if this occurs earlier) or guideline-recommended BP lowering (target SBP < 180 mmHg) after commencement of iv rt-PA.

The protocol originally stated that the intensive group in Arm [B] should have a systolic BP target of 140–150 mmHg within 30 min of randomization. However, it was noted that the systolic BP differences between randomized groups was less than projected (10–14 mmHg). This was because some investigators were overly cautious in their approach to treatment in the intensive group or conversely too aggressive toward the standard care group. Thus, the protocol was changed to the systolic BP target of 130–140 mmHg within 60 min in November 2013.

The site investigator has the choice of continuing or stopping their patients’ antihypertensive medication prior to randomization and they are free to use locally available and approved antihypertensive agents according to a pre-specified treatment protocol. They are to titrate BP by repeat iv bolus or infusion of medication, with a systolic BP of 130 mmHg being the safety threshold for cessation of therapy. Patients are switched to oral BP lowering agents when stable. The study schema is shown in Fig. 1.

For Arm [A] ‘rt-PA dose’, it should be noted that the bolus dose has been set to be similar between treatment groups, so that the only difference between groups is in the total dose of rt-PA.

Background care

All patients will be managed in a facility with an adequate nurse: patient ratio and capacity for repeated neurological examination and non-invasive BP and heart rate monitoring (consistent recordings using automatic devices, every 15 min for one-hour, then 6 hourly for 20 h, then twice daily for one-week). All BP measurements are from the non-paretic arm (or right arm in situations of coma or tetraparesis), with the patient resting supine for ≥3 min. All patients are to receive active care and best practice management according to guidelines, and where neurointervention with intra-arterial thrombolysis and/or endovascular mechanical clot retrieval is allowed according to local practice.

An acute stroke unit is defined as an area that: is a geographically specific area where patients with acute stroke are managed; has staff organized as part of a coordinated multidisciplinary team; has staff who have special knowledge and skills in the management of acute stroke; provides ongoing education about stroke management for staff, patients and caregivers; and has written protocols for assessment and management of common problems related to stroke.

During the study treatment and follow-up period, the usual management of patients will be followed according to published guidelines for AIS. It is anticipated that background care may include significant use of treatments including drugs and endovascular intervention. Use of other therapies will be documented and compared between countries and should be balanced between randomized groups.

Data collection and follow-up

All patients are followed daily for one-week, and then at 28 and 90 days, unless death occurs earlier. Patients who are unable to complete the protocol are still followed up and analyzed according to the ‘intention-to-treat’ principle. Key demographic and clinical data are collected at the time of randomization. Follow-up data is collected at 24 and 72 h, and at 7 (or hospital discharge if sooner), 28 and 90 days. The 90-day evaluation is conducted in-person or by telephone, by trained staff who are blind to the treatment allocation. Brain imaging (CT and/or MRI) is conducted according to standardized techniques at baseline, and at 24 ± 3 h, and additionally if clinically indicated. The scans are collected in DICOM format, de-identified, and analyzed at the ICC. Table 2
**Fig. 1** Study schema.

**Table 2** Schedule of evaluations

<table>
<thead>
<tr>
<th>Evaluation</th>
<th>Prior to randomization</th>
<th>Day 1 and 2</th>
<th>3*</th>
<th>7*</th>
<th>28*</th>
<th>90*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain imaging (CT ± angiogram or MRI)</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BP</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical history, prior medications</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical exam GCS/NIHSS</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Functional assessment with mRS</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HRQoL assessment with EQ5D</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Routine blood tests</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BP lowering treatment</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard stroke care</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalized or not</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact details for follow-up</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*On this day or the day of discharge if prior to days 3 or 7.

†Information is collected at a face-to-face consultation or through a telephone interview.

‡Every 15 min for one-hour after initiation of rt-PA; every 15 min for one-hour after initiation of BP lowering; hourly from one-hour to six-hours after initiation of rt-PA; 6 hourly from six-hours to 24 h after initiation of rt-PA; at any point where intravenous bolus drugs are administered, BP and HR should be recorded 5 and 15 min later.

CT, denotes computerized tomography; EQ5D, 5-dimensions health questionnaire; GCS, Glasgow coma scale; HRQoL, health-related quality of life; MRI, magnetic resonance imaging; mRS, modified Rankin scale; NIHSS, National Institutes of Health stroke scale; rt-PA, recombinant tissue plasminogen activator.
Y. Huang et al.

illustrates the schedule and nature of data collection during the study period. Data entry is completed via a password protected website held by the ICC.

**Study outcomes**

The primary outcome for both Arms of the ENCHANTED trial is the combined endpoint of death and disability as defined by the dichotomized ‘0–1’ (‘excellent outcome’) vs. ‘2–6’ (‘dead or dependent’) on the mRS at 90 days. The secondary outcome for Arm [A] is sICH defined by all major criteria: (a) sICH based on NINDS criteria of brain imaging confirmed ICH with any neurological deterioration (≥1 point change in NIHSS score) from baseline or death within 36 h; and (b) sICH defined by SITS-MOST criteria (30) as large local or remote parenchymal ICH (type 2) combined with a neurological deterioration (≥24 points on the NIHSS) from baseline or death within 36 h. Other outcomes are ICH of any type on brain imaging ≤7 days of treatment; death or disability by the shift analysis of mRS scores (37,38); death; disability; neurological deterioration (≥24 points decline in NIHSS) during 72-h; HRQoL by the EuroQoL (39); admission to residential care; and health service use for calculation of resources and costs.

**Data management**

The study database includes web-based data entry onto electronic Case Report Forms (CRF) developed by The George Institute for Global Health. Each participating hospital site enters data using an electronic signature (unique username and password). All changes that are made have an electronic audit trail with electronic signature and date. Both the ICC and Regional Coordinating Centre (RCC) staff have access to online reports on overall study status, CRF completion status, and serious adverse events (SAE) reports, to assist with monitoring the data quality.

**Quality assurance**

The aim of the non-inferiority trial Arm [A] is to demonstrate that any difference in outcomes between the two doses of rt-PA is small enough to allow a conclusion that the effect of low-dose rt-PA is not inferior to standard-dose rt-PA. We have assumed that effective recanalization of an occluded cerebral artery in AIS is more dependent on the time from the onset of symptoms to injection of the bolus dose of rt-PA rather than the total dose and duration of the subsequent infusion of rt-PA. Thus, the study has been designed with a similar loading dose but differing infusion dose of rt-PA according to body weight between the low-dose and standard-dose treatment arms.

We recognized that the success of a non-inferiority trial is dependent on addressing certain parameters with the potential for bias toward the null, that is where the observed treatment difference decreases from the true difference between treatments. This could arise if there is imprecise or poorly implemented entry criteria, poor adherence to the protocol (including dosing errors or delays in the use of rt-PA), use of concomitant treatments and background care with effects that may overlap with rt-PA, and poor measurement of outcomes. While each of these issues may on their own have only small (or no) influence on the variability of the outcome (variance), collectively they can reduce the observed difference between randomized groups, potentially leading to a false conclusion over non-inferiority. Thus, central monitoring includes regular checks of the accumulating data to ensure sites adhere to the ‘gold standard’ short DTN time (i.e. average 60 min) (9) and the initial estimates of body weight for dosing of rt-PA are checked against measured body weight in patients after they are admitted to stroke units. Independent experienced neurologists review and adjudicate all brain imaging related to all deaths and assess any ICH in all follow-up scans. All CT or MRI images are uploaded onto a secure web-based database which uses MIStar version 3.2.63 (Apollo Medical Imaging Technology, Melbourne, Vic., Australia), to allow blinded assessment.

Central and regionally based, research staff undertake remote monitoring and on-site data verification. The initial on-site monitoring visit takes place after the first few patients are randomized at a site, and thereafter sites are monitored at least every 12 months according to recruitment and data quality. Monitoring serves to confirm that investigators are adhering to the protocol and Good Clinical Practice (GCP) Guidelines, and the accuracy of the data. To ensure adherence to appropriate randomized dose of rt-PA, sites are required to register the Actilyse vial number(s) within 24 h of randomization and store the packages for checking at monitoring visits. Site monitoring by research staff aims to confirm: (i) demographic and consent details of randomized patients; (ii) details of all SAEs against source documents; (iii) collection/correction of outstanding/missing data; and (iv) checking of selected variables against source medical documents in a 10% random selection of patients.

**Data safety monitoring committee (DSMB)**

The external DSMB employs the Haybittle–Peto rule as a guide for proof beyond reasonable doubt in the monitoring of both efficacy and safety information in the trial. The DSMB regularly monitors SAEs (deaths, ICH and neurological deterioration), for which any excess would trigger discussions over stopping for harm.

**Sample size**

Arm [A] ‘rt-PA dose’ primary clinical outcome. The Cochrane review of thrombolysis in AIS notes the rate of death or disability (mRS score of 2–6) in patients treated with standard-dose iv rt-PA as 50%, and non-randomized studies suggest that low-dose rt-PA provides a similar clinical outcome (i.e. risk ratio 1·0) (2,39). For comparison between low- and standard-dose rt-PA, a non-inferiority margin has been proposed that is based on the Cochrane review where the overall risk ratio of standard-dose rt-PA vs. control with respect to death or disability was 0·76 (95% CI 0·66–0·87). Taking a conservative approach, the 40th percentile point around the risk reduction estimate (0·77) rather than the observed risk ratio is taken as the more robust reference to describe the effects of standard-dose rt-PA (this translates into a margin of excess risk of placebo vs. standard-dose rt-PA of 1·29). A non-inferiority margin of 1·14 has been set to provide assurance that low-dose rt-PA retains at least half the efficacy of standard-dose rt-PA, provided the upper limit of 95% CI of low- vs. standard-dose rt-PA is less than this non-inferiority margin (Fig. 2). The sample size takes account of the potential for a negative interaction between intensive BP lowering and low-dose
rt-PA. Resulting calculations produced a sample size of 3300 (1650 per group) to provide at least 90% power (1-sided \(\alpha=0.025\)) to achieve the non-inferiority setting, assuming 5% drop-out. Once non-inferiority has been confirmed, it is then possible to evaluate if low-dose rt-PA is superior to standard-dose rt-PA.

Arm [B] 'BP control' primary clinical outcome. Using results from the SITS-ISTR registry (31) and assuming a potential interaction between low-dose rt-PA and intensive BP lowering, a sample size of 2300 (1150 per group) will provide >90% power (2-sided \(\alpha=0.05\)) to detect a 14% relative reduction in the primary outcome in the intensive BP lowering group, assuming 5% drop-out.

Secondary outcome of sICH in Arm [A] 'rt-PA dose'. Based on past results (2,31,40) and assuming a potential interaction between low-dose rt-PA and intensive BP lowering, a sample size of 3300 (1650 patients per group) will provide >80% power (2-sided \(\alpha=0.05\)) to detect >40% relative reduction in sICH for the low-dose rt-PA group, assuming 5% drop-out.

Secondary outcome of any ICH in Arm [B] BP control. Similarly, the study will provide >90% power (2-sided \(\alpha=0.05\)) to detect reductions in any ICH from intensive BP lowering, assuming 5% drop out.

Statistical analyses
ENCHANTED will follow the intention-to-treat principle for analyses. However, sensitivity per-protocol analysis may also be conducted for non-inferiority analysis. Baseline characteristics will be summarized by treatment groups. The primary end-point of death and disability will be analyzed by a chi-square test, as will the categorical secondary outcomes. In Arm [A], low-dose rt-PA will be considered non-inferior to standard-dose rt-PA with regard to the primary endpoint if the upper limit of the 95% CI for risk ratio is <1.14. Continuous endpoints will be summarized by means or medians, with the treatment effects tested by Wilcoxon test that assumes skewed data. If these data are not acceptably skewed, mixed models will be used to describe the health utility score over time. The primary analysis will be unadjusted. Descriptive statistics will be provided for safety data. SAE and treatment discontinuation due to them will be tabulated using standard terminology. Heterogeneity of treatment on the primary endpoint will be assessed in pre-defined subgroups: age (<65 vs. ≥65 years); gender; time-to-treatment (<3 vs. ≥3 h); systolic BP (above vs below mean); ethnicity (Asia vs. non-Asia); visible cerebral infarction; presumed subtype of AIS (cardio-embolic, lacunar, atherothrombotic, and other); NIHSS at baseline (above vs below median); and evidence of proximal cerebral artery clot occlusion on angiography (yes vs. no). Analyses will be specified a priori in a full statistical analysis plan.

Study organization
The management of ENCHANTED includes a Steering Committee who have overall responsibility for the execution of study design, protocol, data collection and analysis plan, as well as publications. They have the right to appoint new members and co-opt others to add to the integrity of the conduct of the study and analyses. An Operational Committee based at the ICC is in charge of the central coordination of the study. There are RCCs, DSMB, an Imaging Adjudication Committee, and an Advisory Committee of international experts. Approximately 100 sites are responsible for recruiting patients and collecting data in Asia, Australia, South America and the United Kingdom. Hospitals are administratively tied through a structure designed to enhance effective communication and collaboration as well as monitor and maintain operations through adherence to a common protocol.

Current status of the trial and funding
The ENCHANTED trial is currently recruiting patients in approximately 100 centers within 15 countries and overall has randomized more than 2624 patients as of February 2015. Figure 3 and Table 3 show that the great majority of participants are into Arm [A] rt-PA dose as compared to Arm [B] BP control. Table 4 demonstrates that there are comparable baseline demo-

---

**Fig. 2** Illustration and interpretation of non-inferiority boundary for low-dose compared to standard-dose recombinant tissue plasminogen activator (rt-PA). A, low-dose rt-PA is inferior to standard-dose rt-PA; B, indeterminate comparison of efficacy between doses of rt-PA; C, low-dose rt-PA has the same benefit as standard-dose rt-PA; D, low-dose rt-PA is superior to standard-dose rt-PA.
Thrombolytic treatment with iv rt-PA is an established treatment for AIS (1,2,39), with the FDA approved standard-dose of 0·9 mg/kg being proposed after small dose finding studies: escalating doses of rt-PA were administered to patients within 90 min from AIS onset in Part I (4), and between 91 and 180 minutes from onset in Part II (5). No sICH was noted in the 58 patients who received \( \leq 0·85 \) mg/kg iv rt-PA in Part I vs. 3/26 patients who had received a dose of \( \geq 0·95 \) mg/kg. Higher doses of iv rt-PA were significantly related to the risk of sICH, but there was no clear correlation between early neurological improvement and rt-PA dose. Based on these findings, an arbitrary intermediate dose between 0·85 and 0·95 mg/kg was selected for the NINDS efficacy trial (3). However, Japanese authorities subsequently approved a lower dose of 0·6 mg/kg based on concerns of hazard leading to comparable efficacy studies in that population. The better efficacy and safety of this lower dose has been suggested in many studies across Asia as well as part of ‘bridging’ thrombolysis in endovascular treatment trials of AIS in the United States (41).

One of the major drawbacks to the use of iv rt-PA is the major adverse effect of sICH, with an apparent higher risk in particular patient subgroups, including Asians (42) and those who are hypertensive at presentation (30,31). Other drawbacks to iv rt-PA are limited access, service organizational issues, and relatively high cost. As most strokes occur in developing countries, only low-cost treatments that are widely applicable will have significant public health impact. Since low-dose rt-PA and early intensive BP lowering both fulfill these requirements, ENCHANTED could have a major impact in reducing the burden of stroke by providing evidence for a cheaper, safer and effective treatment for AIS, used either alone or in combination. Given the applicability to millions of people with AIS worldwide each year, the results of the

### Table 3

<table>
<thead>
<tr>
<th>Arm [B] ‘BP control’</th>
<th>Standard</th>
<th>Intensive</th>
<th>Not randomized</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm [A] ‘rt-PA dose’</td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
<td>N (%)</td>
</tr>
<tr>
<td>Standard dose rt-PA</td>
<td>133 (6.6)</td>
<td>135 (6.7)</td>
<td>708 (35.4)</td>
<td>976 (48.8)</td>
</tr>
<tr>
<td>Low-dose rt-PA</td>
<td>149 (7.4)</td>
<td>133 (6.6)</td>
<td>700 (35.0)</td>
<td>982 (49.1)</td>
</tr>
<tr>
<td>Not randomized</td>
<td>23 (1.1 )</td>
<td>20 (1.0)</td>
<td>0</td>
<td>43 (2.1)</td>
</tr>
<tr>
<td>Total</td>
<td>305 (15.2)</td>
<td>288 (14.4)</td>
<td>1408 (70.4)</td>
<td>2001 (100)</td>
</tr>
</tbody>
</table>

### Table 4

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), year</td>
<td>66 (13)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>1209 (62)</td>
</tr>
<tr>
<td>China recruitment, n (%)</td>
<td>809 (41)</td>
</tr>
<tr>
<td>Systolic BP, mean (SD) mmHg</td>
<td>149 (20)</td>
</tr>
<tr>
<td>Diastolic BP, mean (SD) mmHg</td>
<td>85 (13)</td>
</tr>
<tr>
<td>NIHSS, mean (SD)</td>
<td>10 (6)</td>
</tr>
<tr>
<td>Body weight, mean (SD), kg</td>
<td>70 (15)</td>
</tr>
<tr>
<td>Time from onset to hospital arrival, median (iqr), hours</td>
<td>1·3 (0·8–2·0)</td>
</tr>
<tr>
<td>CT or MRI angiography shows cerebral artery occlusion, n (%)</td>
<td>321 (16)</td>
</tr>
<tr>
<td>One-hour, post-randomization, systolic BP difference between treatment groups, mmHg</td>
<td>0</td>
</tr>
</tbody>
</table>

NIHSS denotes National Institutes of Health stroke scale; BP, blood pressure; CT, computerized tomography; MRI, magnetic resonance imaging.

**Conclusion**

Thrombolytic treatment with iv rt-PA is an established treatment for AIS (1,2,39), with the FDA approved standard-dose of 0·9 mg/kg being proposed after small dose finding studies: escalating doses of rt-PA were administered to patients within 90 min from AIS onset in Part I (4), and between 91 and 180 minutes from onset in Part II (5). No sICH was noted in the 58 patients who received \( \leq 0·85 \) mg/kg iv rt-PA in Part I vs. 3/26 patients who had received a dose of \( \geq 0·95 \) mg/kg. Higher doses of iv rt-PA were significantly related to the risk of sICH, but there was no clear correlation between early neurological improvement and rt-PA dose. Based on these findings, an arbitrary intermediate dose between 0·85 and 0·95 mg/kg was selected for the NINDS efficacy trial (3). However, Japanese authorities subsequently approved a lower dose of 0·6 mg/kg based on concerns of hazard leading to comparable efficacy studies in that population. The better efficacy and safety of this lower dose has been suggested in many studies across Asia as well as part of ‘bridging’ thrombolysis in endovascular treatment trials of AIS in the United States (41).

One of the major drawbacks to the use of iv rt-PA is the major adverse effect of sICH, with an apparent higher risk in particular patient subgroups, including Asians (42) and those who are hypertensive at presentation (30,31). Other drawbacks to iv rt-PA are limited access, service organizational issues, and relatively high cost. As most strokes occur in developing countries, only low-cost treatments that are widely applicable will have significant public health impact. Since low-dose rt-PA and early intensive BP lowering both fulfill these requirements, ENCHANTED could have a major impact in reducing the burden of stroke by providing evidence for a cheaper, safer and effective treatment for AIS, used either alone or in combination. Given the applicability to millions of people with AIS worldwide each year, the results of the
ENCHANTED trial could have a major impact on the current clinical practice.

**Acknowledgements**


*Advisory Committee:* Philip Bath, Joseph Broderick, Andrew Demchuk, Geoffroy Donnan.

*Data Safety Monitoring Board:* R John Simes, Graeme Hankey, Peter Sandercock, Marie-Germaine Bousser, KS Lawrence Wong.

*International Coordinating Center:* Xiaoying Chen, Joyce Lim, Elizabeth Knight, Sharon Tucker, Leibo Liu, Sully Fuentes, Elizaveta Ivanova, Cheryl Carcel, Elizabeth Odgers, Elizabeth Sanders, Emma Thembani, Ruchita Vaghasiya, Kerry Jenson, Xia Wang.

*Regional Coordinating Centers:* South America – Veronica Olavarría, Francisca Gonzalez, Bernardita Portales, Alejandra Malaver, Magda Carla Ouriques Martins; China – Ying Guo, Zwei Xu, Zhen Xi, Ting Zhang, Yan Zhao, Nan Li, Roulan Jia, Wei Li; South Korea – Yunjeong In, Su Jin Kim, Jung Eun Ahn; Taiwan – Chinyi Yi Wang, Shan-Jin Ryu; United Kingdom – Tracy Kumar, Alice Durham, Hardeep Aujla; Vietnam – Hong Ha Uyen.

**References**


10. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. *Arch Neurol* 2004; **61**:1066–70.


